Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.

Autor:	Atallah E; Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK., Welsh SJ; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., O'Carrigan B; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Oshaughnessy A; Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Dolapo I; Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK., Kerr AS; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Kucharczak J; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Lee CYC; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Crooks C; Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK., Hicks A; Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Chimakurthi CR; Leeds Liver Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Rao A; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Franks H; Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Centre for Cancer Sciences, Translational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham, UK., Patel PM; Department of Oncology, Nottingham University Hospitals NHS Trust, Nottingham, UK.; Centre for Cancer Sciences, Translational Medical Sciences, Biodiscovery Institute, University of Nottingham, Nottingham, UK., Aithal GP; Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; National Institute for Health Research (NIHR) Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
Jazyk:	angličtina
Zdroj:	JHEP reports : innovation in hepatology [JHEP Rep] 2023 Jul 18; Vol. 5 (10), pp. 100851. Date of Electronic Publication: 2023 Jul 18 (Print Publication: 2023).
DOI:	10.1016/j.jhepr.2023.100851
Abstrakt:	Background & Aims: Checkpoint inhibitors (CPI) account for increasing numbers of drug-induced liver injury (DILI) cases. We aimed to determine the incidence rate and risk factors associated with checkpoint inhibitor-induced liver injury (ChILI). Methods: Prescription event monitoring was performed on all melanoma and renal cancer patients who received CPI at a tertiary centre between 2011 and 2021. ChILI cases were identified using the definitions, grading, and causality assessment methods validated for DILI. We assessed risk factors associated with ChILI in CPI-naive patients using multivariable logistic regression model. Consecutive patients with suspected ChILI from two other tertiary centres were adjudicated and combined for case characterisation and outcomes of ChILI. Results: Out of 432 patients who received CPI over 10 years, ChILI occurred in 38 (8.8%) with an overall incidence rate of 11.5 per 1,000 person-months (95% CI 8.2-15.8). Probability of ChILI was highest in combination therapy (32%) and no new events occurred beyond 135 days of treatment. Risk factor analysis showed that combination therapy, female sex, higher baseline alanine transferase level and lower baseline alkaline phosphatase level were independently associated with higher risk of ChILI. In total, 99 patients were adjudicated to have ChILI from three centres. Although Common Terminology Criteria for Adverse Events classified 20 patients (20.2%) to have 'life-threatening' grade 4 hepatitis, ChILI severity was graded as mild in 45 (45.5%) and moderate in the remaining 54 (54.5%) cases. Conclusions: The real-world risk of ChILI is higher than previously reported. Among patients receiving dual CPI, this risk falls markedly after 4.5 months. As Common Terminology Criteria for Adverse Events overestimates its clinical severity, case-definition, evaluation and management of ChILI should be revised to harmonise care. Impact and Implications: Using prescription event monitoring over a 10-year period, the incidence rate of checkpoint inhibitor induced liver injury (ChILI) based on established case definitions for drug-induced liver injury (DILI) is 11.5 per 1,000 person-months. Formal causality assessment identified an alternative cause in 19% of patients with suspected ChILI highlighting the importance of systematic evaluation by clinicians to minimise unnecessary immunosuppression. Intensity of monitoring in patients receiving combination therapy regime after 4.5 months of therapy can be reduced as the risk of new onset ChILI beyond this point is minimal. Current Common Terminology Criteria for Adverse Events (CTCAE) grading overestimates clinical severity of ChILI and hence contributes to avoidable hospitalisation. Competing Interests: GPA has received consulting fees from Pfizer, GlaxoSmithKline, Clinicpace, Servier Pharmaceuticals, NuCANA Plc, AstraZeneca, and BenevolentAI paid to the University of Nottingham. All authors declare no conflicts of interest that relate to this work. Please refer to the accompanying ICMJE disclosure forms for further details. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu